{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:12:47Z","timestamp":1787242367644,"version":"build-2736575974"},"reference-count":41,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The cardiovascular (CV) safety of oral bisphosphonates (oBPs) is uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Determine the risk of CV events in oBP users referred for bone mineral density (BMD) testing compared with matched controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Danish national prescription registry enriched with local hospital data from Odense.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Individuals aged \u226545 years referred for BMD testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>oBP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Hospitalization for any CV event. Secondary study outcomes were specific CV events. Negative (inguinal hernia surgery and ingrown toenail) and positive (fragility fracture) control outcomes assessed systemic bias. Cox proportional hazards models were fitted to estimate hazard ratio (HR) and 95% confidence intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 2565 oBP users (82.6% women) and 4568 (82.3% women) propensity score\u2013matched controls. Alendronate accounted for 96% of oBP prescription. A total of 406 (15.8%) CV events occurred in oBP users (rate = 73.48 [66.67-80.98]); rate = events divided by person-time; and 837 (18.3%) events in controls (rate = 104.73 [97.87-112.07]) with an adjusted HR of 0.68 (95% CI 0.60-0.77). Additional adjustment for BMD did not attenuate estimates (HR 0.67; 95% CI 0.58-0.78]. Similar results were seen for secondary outcomes where risk reductions were seen regarding atrial fibrillation, stroke, heart failure, and aneurysms. Positive and negative control outcome analyses identified minimal residual confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oral BP users experienced a 33% reduced risk of CV events. This observational real-world study adds to a growing body of evidence for cardioprotection by oBP that warrants testing in a randomized setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa481","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T15:08:50Z","timestamp":1595862530000},"page":"3215-3225","source":"Crossref","is-referenced-by-count":29,"title":["Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-0642","authenticated-orcid":false,"given":"Alexander J","family":"Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Bone and Muscle Health Research Group, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia"},{"name":"OPEN-Open Patient Data Explorative Network, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin T","family":"Ernst","sequence":"additional","affiliation":[{"name":"OPEN-Open Patient Data Explorative Network, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Nybo","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Prieto-Alhambra","sequence":"additional","affiliation":[{"name":"Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"},{"name":"Grup de Recerca en Malalties Prevalents de l\u2019Aparell Locomotor (GREMPAL) Research Group and CIBERFes, University Institute for Primary Care Research (IDIAP) Jordi Gol, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R","family":"Ebeling","sequence":"additional","affiliation":[{"name":"Bone and Muscle Health Research Group, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia"},{"name":"Australian Institute for Musculoskeletal Science, Melbourne Medical School-Western Campus, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Pernille","family":"Hermann","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Abrahamsen","sequence":"additional","affiliation":[{"name":"OPEN-Open Patient Data Explorative Network, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"},{"name":"Department of Medicine, Holb\u00e6k Hospital, Holb\u00e6k, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"issue":"10","key":"2021122106020775400_CIT0001","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00198-007-0386-0","article-title":"Cardiovascular diseases and future risk of hip fracture in women","volume":"18","author":"Sennerby","year":"2007","journal-title":"Osteoporos Int."},{"issue":"15","key":"2021122106020775400_CIT0002","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1001\/jama.2009.1463","article-title":"Cardiovascular diseases and risk of hip fracture","volume":"302","author":"Sennerby","year":"2009","journal-title":"JAMA."},{"issue":"5","key":"2021122106020775400_CIT0003","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"JAMA."},{"issue":"4","key":"2021122106020775400_CIT0004","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/jbmr.2393","article-title":"Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: the Dubbo Osteoporosis Epidemiology Study","volume":"30","author":"Bliuc","year":"2015","journal-title":"J Bone Miner Res."},{"issue":"8763","key":"2021122106020775400_CIT0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0140-6736(91)90489-C","article-title":"Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group","volume":"338","author":"Browner","year":"1991","journal-title":"Lancet."},{"issue":"1","key":"2021122106020775400_CIT0006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00198-013-2457-8","article-title":"Association between hypertension and fragility fracture: a longitudinal study","volume":"25","author":"Yang","year":"2014","journal-title":"Osteoporos Int."},{"issue":"10","key":"2021122106020775400_CIT0007","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S1047-2797(03)00062-0","article-title":"Bone mineral density and mortality in women and men: the NHANES I epidemiologic follow-up study","volume":"13","author":"Mussolino","year":"2003","journal-title":"Ann Epidemiol."},{"issue":"6","key":"2021122106020775400_CIT0008","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/aje\/kwh080","article-title":"Metacarpal cortical area and risk of coronary heart disease: the Framingham Study","volume":"159","author":"Samelson","year":"2004","journal-title":"Am J Epidemiol."},{"issue":"1","key":"2021122106020775400_CIT0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1359\/jbmr.090704","article-title":"Potential mediators of the mortality reduction with zoledronic acid after hip fracture","volume":"25","author":"Col\u00f3n-Emeric","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"11","key":"2021122106020775400_CIT0010","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamainternmed.2019.2779","article-title":"Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis","volume":"179","author":"Cummings","year":"2019","journal-title":"JAMA Intern Med."},{"issue":"4","key":"2021122106020775400_CIT0011","doi-asserted-by":"crossref","first-page":"e0122646","DOI":"10.1371\/journal.pone.0122646","article-title":"Bisphosphonates and risk of cardiovascular events: a meta-analysis","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS ONE."},{"issue":"9","key":"2021122106020775400_CIT0012","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1517\/14740338.2014.939169","article-title":"Cardiac concerns associated with strontium ranelate","volume":"13","author":"Reginster","year":"2014","journal-title":"Expert Opin Drug Saf."},{"issue":"12","key":"2021122106020775400_CIT0013","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S2213-8587(19)30346-8","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study","volume":"7","author":"McClung","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"15","key":"2021122106020775400_CIT0014","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med."},{"key":"2021122106020775400_CIT0015","author":"Saag"},{"issue":"16","key":"2021122106020775400_CIT0016","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"issue":"9","key":"2021122106020775400_CIT0017","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/jbmr.3809","article-title":"Complementarity of cohort studies and randomized controlled trials","volume":"34","author":"Eisman","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2021122106020775400_CIT0018","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/jbmr.3539","article-title":"The emperor\u2019s new clothes: what randomized controlled trials don\u2019t cover","volume":"33","author":"Eisman","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2021122106020775400_CIT0019","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/joim.12087","article-title":"Heart failure in patients treated with bisphosphonates","volume":"274","author":"Grove","year":"2013","journal-title":"J Intern Med."},{"issue":"5","key":"2021122106020775400_CIT0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2796.2008.02065.x","article-title":"Atrial fibrillation in fracture patients treated with oral bisphosphonates","volume":"265","author":"Abrahamsen","year":"2009","journal-title":"J Intern Med."},{"key":"2021122106020775400_CIT0021","doi-asserted-by":"crossref","first-page":"115296","DOI":"10.1016\/j.bone.2020.115296","article-title":"Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries","volume":"134","author":"Rubin","year":"2020","journal-title":"Bone."},{"issue":"8","key":"2021122106020775400_CIT0022","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/jbmr.3448","article-title":"Association of alendronate and risk of cardiovascular events in patients with hip fracture","volume":"33","author":"Sing","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"7624","key":"2021122106020775400_CIT0023","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ."},{"key":"2021122106020775400_CIT0024"},{"issue":"9","key":"2021122106020775400_CIT0025","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"key":"2021122106020775400_CIT0026","first-page":"S376","article-title":"Cardiovascular safety of zoledronic acid compared with oral bisphosphonates and untreated population controls: an observational cohort study using Danish and Swedish National Health registries","author":"Abrahamsen","year":"2017","journal-title":"ASBMR 2017"},{"key":"2021122106020775400_CIT0027","author":"Rodriguez"},{"issue":"10170","key":"2021122106020775400_CIT0028","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Armitage","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"2021122106020775400_CIT0029","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/odi.12908","article-title":"Alteration of macrophage viability, differentiation, and function by bisphosphonates","volume":"24","author":"Patntirapong","year":"2018","journal-title":"Oral Dis."},{"key":"2021122106020775400_CIT0030","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2147\/CIA.S137403","article-title":"Inappropriate pharmacological treatment in older adults affected by cardiovascular disease and other chronic comorbidities: a systematic literature review to identify potentially inappropriate prescription indicators","volume":"12","author":"Lucenteforte","year":"2017","journal-title":"Clin Interv Aging."},{"issue":"18","key":"2021122106020775400_CIT0031","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"2021122106020775400_CIT0032","doi-asserted-by":"crossref","first-page":"2042098619838138","DOI":"10.1177\/2042098619838138","article-title":"Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy","volume":"10","author":"Kirchmayer","year":"2019","journal-title":"Ther Adv Drug Saf."},{"issue":"11","key":"2021122106020775400_CIT0033","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1532-5415.2011.03666.x","article-title":"Once-yearly zoledronic acid in older men compared with women with recent hip fracture","volume":"59","author":"Boonen","year":"2011","journal-title":"J Am Geriatr Soc."},{"issue":"25","key":"2021122106020775400_CIT0034","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med."},{"issue":"6","key":"2021122106020775400_CIT0035","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00198-020-05379-z","article-title":"Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab","volume":"31","author":"Cummings","year":"2020","journal-title":"Osteoporos Int."},{"issue":"6","key":"2021122106020775400_CIT0036","doi-asserted-by":"crossref","first-page":"e0198006","DOI":"10.1371\/journal.pone.0198006","article-title":"Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: a prospective cohort study","volume":"13","author":"van Geel","year":"2018","journal-title":"PLoS ONE."},{"issue":"5","key":"2021122106020775400_CIT0037","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jbmr.3961","article-title":"Oral bisphosphonate use and all-cause mortality in patients with moderate\u2013severe (grade 3B-5D) chronic kidney disease: a population-based cohort study","volume":"35","author":"Alarkawi","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2021122106020775400_CIT0038","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00198-018-4386-z","article-title":"Nonlinear association between bone mineral density and all-cause mortality: the Dong-gu study","volume":"29","author":"Choi","year":"2018","journal-title":"Osteoporos Int."},{"issue":"5","key":"2021122106020775400_CIT0039","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00198-010-1331-1","article-title":"Low bone mineral density is associated with increased mortality in elderly men: MrOS Sweden","volume":"22","author":"Johansson","year":"2011","journal-title":"Osteoporos Int."},{"issue":"8","key":"2021122106020775400_CIT0040","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1359\/jbmr.070412","article-title":"Bone loss, weight loss, and weight fluctuation predict mortality risk in elderly men and women","volume":"22","author":"Nguyen","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2021122106020775400_CIT0041","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/jbmr.3374","article-title":"Comorbidities only account for a small proportion of excess mortality after fracture: a record linkage study of individual fracture types","volume":"33","author":"Chen","year":"2018","journal-title":"J Bone Miner Res."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa481\/33535959\/dgaa481.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/10\/3215\/41828451\/dgaa481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/10\/3215\/41828451\/dgaa481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T01:02:35Z","timestamp":1640048555000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/10\/3215\/5876920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,7,27]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa481","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,7,27]]}}}